Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05050942 · ClinicalTrials.gov registry record · Phase 3
A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET
A Phase 3 study of Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Camurus AB.
- Active
- Registry status
- Phase 3
- Development phase
- 332
- Enrollment target
- 20
- Study locations
NCT05050942: Active Phase 3 study of Gastroenteropancreatic Neuroendocrine Tumor, sponsored by Camurus AB.
NCT05050942 is a Phase 3 study of Gastroenteropancreatic Neuroendocrine Tumor that is active but no longer recruiting, run by Camurus AB. The registered enrollment target is 332 participants, below the 484-participant average among 7 other Gastroenteropancreatic Neuroendocrine Tumor trials with a reported enrollment target (31% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05050942, a Phase 3 study of Gastroenteropancreatic Neuroendocrine Tumor, is active but no longer recruiting, sponsored by Camurus AB.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 332 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.
Primary Outcome
PFS is defined as time from the date of randomization to the date of the first documented disease progression as per RECIST 1.1 or death due to any cause (whichever occurs first)
Conditions Studied
Interventions
- DRUG Octreotide LAR
- DRUG CAM2029
- DRUG Lanreotide ATG
Study Locations (20)
Texas
- Texas Oncology - Austin - Austin
- Texas Oncology - Dallas - Dallas
- Texas Oncology - Denton North - Denton
- The University of Texas - MD Anderson Cancer Center - Houston
- Texas Oncology - McAllen - McAllen
- Texas Oncology - San Antonio Northeast - San Antonio
New York
- Memorial Sloan-Kettering Cancer Center - New York
- The Mount Sinai Hospital - The Bronx
- White Plains Hospital - Center for Cancer Care - White Plains
Florida
- Mayo Clinic Hospital - Florida - Jacksonville
- Anderson Family Cancer Institute - Jupiter
Arizona
- Mayo Clinic Cancer Center (MCCC) - Phoenix - Phoenix
California
- UCLA Ahmanson Biological Imaging Center - Santa Monica
Colorado
- Rocky Mountain Cancer Centers - Denver - Midtown - Denver
Kentucky
- University of Kentucky (UK) - Markey Cancer Center - Lexington
Louisiana
- East Jefferson General Hospital - Metairie
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 332 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2028-07 |
| Phase | Phase 3 |
What the registry record for NCT05050942 still lists
NCT05050942 is an interventional study that assigns participants to a tested intervention. The registered 332 participants enrollment target is mid-sized for trials with a published cap, below the 484-participant average among 7 other Gastroenteropancreatic Neuroendocrine Tumor trials with a reported enrollment target (31% lower).
The record links to 1 condition, with Gastroenteropancreatic Neuroendocrine Tumor appearing as the primary indexed condition, and to 3 interventions - of which Octreotide LAR is the first listed.
NCT05050942 names 20 study sites across 12 states, led by Texas, New York, Florida.
Frequently Asked Questions
What is clinical trial NCT05050942 about?
NCT05050942 is a clinical study titled "A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET". The purpose of this study is to compare the effectiveness and safety of CAM2029 to octreotide LAR or lanreotide ATG in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with...
What is the current status of trial NCT05050942?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 332 participants. The study started on 2021-10-22. Estimated completion is 2028-07.
What conditions does trial NCT05050942 study?
This clinical trial studies the following conditions: Gastroenteropancreatic Neuroendocrine Tumor.
What interventions are being tested in trial NCT05050942?
The interventions under investigation include: Octreotide LAR (DRUG), CAM2029 (DRUG), Lanreotide ATG (DRUG).
Who is sponsoring clinical trial NCT05050942?
This trial is sponsored by Camurus AB, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05050942 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Gastroenteropancreatic Neuroendocrine Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET
ACTIVE NOT RECRUITING · Phase 3
-
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
RECRUITING · Phase 1
-
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors
RECRUITING · Phase 1
-
Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors
RECRUITING
-
NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174121 · 332 participants · Phase 2
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer
- NCT02605785 · 332 participants · NA
A Molecular Anatomic Imaging Analysis of Tau in Progressive Supranuclear Palsy
- NCT04894006 · 332 participants · NA
Dementia Family Caregiver Study
- NCT05130606 · 332 participants · NA
CONTIGO - A Narrative Intervention to Enhance Genetic Counseling and Testing
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI